News

2017-10-02
Immunovia AB on track regarding application for listing on Nasdaq Stockholm’s main market

As previously announced, the company’s preparations of internal processes to meet the requirements on Nasdaq Stockholm’s main market were expected to be completed in September for initiation of the formal listing process. This goal has been achieved and Nasdaq reviews and formal processes will now follow as planned with the goal to list the company on Nasdaq Stockholm’s main market.
Release

2017-09-26
Management and employees of Immunovia subscribe for new shares by exercising warrants


Release

2017-09-07
Immunovia announces collaboration with Lund University Diabetes Centre for the early detection of pancreatic cancer in diabetes risk group

LUND, Sweden ― Immunovia AB is delighted to announce a collaboration with the researchers at Lund University Diabetes Centre (LUDC) to validate the company´s biomarker signature in high risk group of newly-onset type 2 diabetics (NoD) patients over the age of 50. The risk of these patients to develop pancreatic cancer is over 8 times greater than that of the general population. 
PR Immunovia LUDC retro diabetes ENG

2017-08-23
Immunovia Interim report, January-June 2017

“During Q2 we announced that we are establishing our American office in Boston. The head office for the US includes our own reference laboratory that complements our earlier collaboration with Knight Diagnostic Laboratories and gives us delivery capacity in both the east and west of the United States.” “Another highlight for Immunovia during the quarter was the excellent results from the study of differentiation of Rheumatoid Arthritis (RA), Sjögren’s Syndrome and Systemic Vasculitis. These results complement the ones from the earlier differential study that we presented for SLE in Q1. They further confirm that our IMMrayTMplatform is generally applicable for many unsolved clinical problems within both cancer and autoimmunity while specifically strengthening our possibilities in the autoimmunity field.” “During the quarter we announced that, together with Knight Cancer Institute at OHSU, we received a research grant from PanCAN, a patient advocacy group, to support a retroactive analysis of American patients who developed pancreatic cancer after being diagnosed with diabetes.”
Release

2017-08-18
Immunovia invites to a conference call on August 23, 2017

Immunovia invites to a conference call in connection with reporting the half-year results 2017. The conference call will take place at 16:00 on August 23 and the result is expected to be published at 8:30 AM the same day.
Release

2017-07-17
Leading expert on pancreatic cancer, Professor Stephen Pereira at University College London, joins Immunovia’s Scientific Advisory Board

LUND, Sweden ― Immunovia announced today that Professor Stephen Pereira, one of the globally leading experts in the diagnosis of early symptoms of pancreatic cancer and a multidisciplinary diagnostic center champion has been appointed to the company’s Scientific Advisory Board. Currently, Pereira is Professor of Hepatology & Gastroenterology at UCL, University College London, and an honorary consultant in pancreaticobiliary medicine at UCL Hospitals and The Royal Free Hospital.  
Release

2017-06-30
Immunovia together with Oregon Health and Science University awarded one of the Pancreatic Cancer Action Network 2017 Research Grants

LUND, Sweden ― On the 28th of June, it was announced that Pancreatic Cancer Action Network (PanCAN), the largest patient advocacy group in USA, in partnership with generous donors, awarded Prof. Brett Sheppard and Prof. Rosalie Sears from Oregon Health and Science University one of the Research grants for 2017 of a value of $ 250.000.
Release

2017-06-28
Immunovia establishes US headquarters, including CLIA reference laboratory, in Boston

LUND, Sweden ― Immunovia today announces that Boston, Massachusetts USA, has been chosen as the location for the headquarters of Immunovia Inc, a wholly owned subsidiary of Immunovia AB, and that the facility agreements have been finalized.  This new Immunovia site is designed to accommodate a CLIA accredited reference laboratory for the Eastern USA as well as facilitating commercialization, covering marketing, sales and customer support.
Release

2017-06-21
Immunovia’s IMMray™ presents biomarkers that differentiates Rheumatoid Arthritis from other autoimmune diseases with 89% accuracy

LUND, Sweden - Immunovia today announced that they have completed the analysis of the three other autoimmune diseases included in the previously reported large, retrospective autoimmune disease study, performed in collaboration with Department of Immuntechnology, Lund University. The study included 315 blood samples and covered main autoimmune indications such as, Systemic Lupus Erythematosus Rheumatoid Arthritis (RA), Sjögren’s Syndrome, Systemic Vasculitis and healthy controls. For SLE, two sets of differential diagnosis data were previously reported March 7 2017.
Release

2017-06-16
Immunovia AB announces timetable for listing on Nasdaq Stockholm's main market

LUND, Sweden - The Board of Directors of Immunovia AB today announces timetable for the application for listing of the company's shares on Nasdaq Stockholm's main market. Immunova's shares are currently traded on Nasdaq First North under the ticker IMMNOV.
Release

2017-06-13
Immunovia´s biomarker signature for the diagnosis of pancreatic cancer now patented in Japan

LUND, Sweden ― Immunovia is delighted to announce the grant by the Japanese Patent Office of a patent for its biomarker signature for the diagnosis of pancreatic cancer.  Japanese Patent No. JP 6115801, is the first patent awarded to Immunovia in Japan covering its proprietary IMMray™ PanCan-d test. 
Release

2017-04-25
Immunovia Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299, har hållits den 25 april 2017 i Gamla Gästmatsalen på Medicon Village, Scheelevägen 2, Lund. Nedan följer en sammanfattning av de beslut som fattades.
Release

2017-04-20
Immunovia Interim report, January-March 2017


Release

2017-04-19
Immunovia inbjuder till telefonkonferens den 20 april 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av första kvartalet 2017. Telefonkonferensen äger rum kl. 16:00 den 20 april och resultatet beräknas publiceras kl. 8:30 samma dag.
Release

2017-03-24
IMMUNOVIA AB KALLAR TILL ÅRSSTÄMMA OCH PUBLICERAR ÅRSREDOVISNING FÖR RÄKENSKAPSÅRET 2016


Release

2017-03-07
Final data from major Swedish study confirms that IMMray™ biomarker microarray differentiates SLE from other autoimmune diseases with 96% accuracy

LUND, Sweden: Immunovia today announced that the large retrospective autoimmune disease study, performed in collaboration with Lund University’s IDEA Centre has been finalized. The study, first reported in January 2017, included 315 blood samples and was specifically designed to assess the effectiveness of IMMray™ blood-based biomarker signatures in differentiating SLE from three other main autoimmune diseases: rheumatoid arthritis, Sjögren disease and vasculitis. There is a clear clinical need for such a test since more than 50% of SLE patients are being initially misdiagnosed, mainly due to ambiguous laboratory test results.
Release

2017-02-22
Immunovia tillkännager genomförd blocktransaktion i bolagets aktier


Release

2017-02-15
Immunovia Financial Statement 2016


Release

2017-02-14
Immunovia inbjuder till telefonkonferens den 15 februari 2017

Immunovia inbjuder till telefonkonferens i samband med rapportering av helårsresultatet för 2016. Telefonkonferensen äger rum kl. 16.00 den 15 februari och resultatet beräknas publiceras kl. 08.00 samma dag.
Release

2017-02-13
Immunovia presenterar vid Vator Securities Unicorn Summit

Vator Securities Unicorn Summit är en kapitalmarknadsdag med några av de mest intressanta svenska Life Science-bolagen. Eventet anordnas den 7 mars 2017 på IVA i Stockholm, med start klockan 11.30.
Release

2017-01-16
University of Michigan Pancreatic Cancer Center new partner in Immunovia’s global PANFAM-1 prospective validation study

LUND, Sweden, and Ann Arbor, USA ― Immunovia AB is pleased to announce that the University of Michigan Pancreatic Cancer Center has become the most recent member of the global network of prominent sites participating in the PANFAM-I prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals.
Release

2017-01-13
Immunovia bjuder in till telefonkonferens tisdag 17/1 kl 16:00

Med anledning av gårdagens offentliggörande av studieresultaten där Immunovia kan påvisa att IMMray™ biomarkörsignatur kan särskilja Systemic Lupus Erythematosus (SLE) med 90 procents träffsäkerhet från andra autoimmuna sjukdomar, inbjuder Immunovia till telefonkonferens på tisdag 17 januari, kl 16:00.
Release

2017-01-12
Immunovia announces first data exceeding 90% accuracy in distinguishing systemic lupus erythematosus (SLE) from other autoimmune diseases in new study

LUND, Sweden ― Immunovia today announced that the principal aim of a large retrospective study, performed in collaboration with Lund University’s IDEA Centre, has been achieved. The data confirms that IMMray™ biomarker signatures can distinguish Systemic Lupus Erythematosus (SLE) from three other main autoimmune diseases, rheumatoid arthritis, Sjögren’s disease and vasculitis with an average accuracy exceeding 90%. These results are extremely encouraging because the symptoms of SLE mimic other rheumatic, autoimmune diseases leading to more than 50% of the patients being initially misdiagnosed, mainly due to ambiguous laboratory test results. It is estimated that as many as 5 million people suffer from SLE and it may take up to 3 years from symptoms appearing to diagnosis and treatment.
Immunovia press release SLE

2016-12-22
Immunovia Shareholder Newsletter Q4 2016

Dear Immunovia Shareholders, With the end of the year approaching and many of you looking forward to a well-deserved Christmas and New Year celebration, we at Immunovia would also like you to join us in celebrating an unprecedented year which we are sure you would agree has more than surpassed expectations. In this newsletter, we would like to give you a summary of the milestones and highlights of a highly successful 2016 and the outlook for what is shaping up already to be an equally productive 2017. In particular 2016 was an exciting year as we started implementing Immunovia’s commercialization plan focussing on the goal of achieving reimbursement and national guideline status.
Release

2016-12-20
Immunovia announces the start of PANFAM-1, the largest ever prospective multi-center clinical study for early detection of pancreatic cancer

Designed to validate IMMrayTM PanCan-d, the first blood-based test for early detection of pancreatic cancer.
Release

2016-12-09
Summary from the extraordinary general meeting of Immunovia

Extraordinary General Meeting of Immunovia AB (publ), 556730-4299, has been held in the confernce room ”Gamla Gästmatsalen”, House 302, Medicon Village, Scheelevägen 2, 223 63 Lund, December 9, 2016. Below is a summary of the resolutions of the extraordinary general meeting.
Release

2016-12-09
Immunovia announces collaboration with NCI, regarding early detection of pancreatic cancer in the new onset diabetes risk group

Immunovia and NCI (National Cancer Institute), has in a memorandum of understanding agreed to collaborate towards a common goal of cancer biomarker development and validation, in particular regarding early detection of pancreatic cancer in the risk group of new onset diabetes over 50 years.
Release

2016-12-09
Immunovia announces collaboration with the renowned Ramon y Cajal Institute for Health Research (IRYCIS) in Madrid

LUND, Sweden, and MADRID, Spain ― Immunovia AB is delighted to announce the addition of the leading Spanish research centre Ramon y Cajal Institute for Health Research (IRYCIS) to a global network of leading sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer in high risk individuals. Designed to validate Immunovia ́s blood test, IMMrayTM PanCan-d, the study will run for three years across sites in both the US and Europe that offer high risk pancreatic cancer screening programs. 
Release

2016-11-18
Immunovia awarded 2016 Stars of Innovation Prize

Leading-edge healthcare diagnostics company making major progress in Europe.
Release

2016-11-16
KALLELSE TILL EXTRA BOLAGSSTÄMMA I IMMUNOVIA AB (publ)


Release

2016-11-15
WORLD PANCREATIC CANCER DAY, LUND SWEDEN, November 17, 2016 - It's About Time

Every day, more than 900 people around the world die from pancreatic cancer. Only 6 percent of the patients diagnosed with pancreatic cancer survive 5 years. According to a recent global survey, more than 60 percent of people know “almost nothing” about pancreatic cancer.
Release

2016-10-19
Immunovia announces completion of preferential rights issue of SEK 28.7 million, adding to previously SEK 189.9 million directed issue

(LUND, Sweden) ― Immunovia AB, the Swedish molecular diagnostics company, announces today that it has successfully completed its SEK 28.7 million rights issue of which the subscription period ended on Monday October 17th. The underwriters, who had guaranteed 52% of the rights issue, will thereby not be assigned any shares through their guarantee.
Release

2016-10-13
Immunovia chosen as one of the three most innovative small to mid-companies in Europe 2016

Stars of Innovation nomination recognizes stellar performance since IPO
Release

2016-10-07
Immunovia: Insiders transfer subscription rights free of charge

LUND, Sweden ― Within the framework of the ongoing rights issue at Immunovia AB (publ) ("the company ") Carl Borrebaeck and Christer Wingren, Chairman of the Board and Chief Technical Officer respectively at the company, have, on request from professional investors and in consultation with the company's financial advisor Vator Securities, transferred all subscription rights received in the rights issue to named investors.
Press release PDF

2016-09-26
Immunovia publishes prospectus regarding preferential rights issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia publishes prospectus regarding preferential rights issue Immunovia AB (publ) (”Immunovia” or the ”Company”) publishes prospectus in connection with the Company’s preferential rights issue (the “Rights Issue”). Publication of prospectus Immunovia’s prospectus, prepared in connection with the Rights Issue, has today been approved and registered by the Swedish Financial Supervisory Authority. The prospectus has today been published and is also available on the company’s web page http://immunovia.com/investors/ and the Company’s head office.
Press release PDF

2016-09-15
The board of directors of Immunovia resolves on a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. The board of directors of Immunovia resolves on a directed and preferential right issue
Press release Immunovia resolves on a directed and preferential right issue

2016-09-14
Immunovia intends to launch a directed and preferential right issue

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS. Immunovia intends to launch a directed and preferential right issue Summary Immunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch a directed share issue of approximately 2 300 000 of shares. Thereafter, the Company, intends to launch a new share issue amounting to approximately SEK 30 million with preferential right for the Company’s existing shareholders.
Press release PDF

2016-09-05
Immunovia holdig detailed talks about participation in a large consortium that will address the largest risk group for pancreatic cancer

The best chance to influence the survival of non-hereditary pancreatic cancer patients is to focus on early detection of cases in people aged over 50 who receive their first diagnosis of diabetes. There is now clear unanimity on this, and both public authorities and health institutes focused on the link between diabetes and pancreatic cancer are initiating research programmes on a large scale across several countries in order to identify and assess the best ways to reduce fatality through early detection of pancreatic cancer among the diabetes risk group.
Press release PDF

2016-08-24
Immunovia Half-year report 2016


Press release PDF

2016-08-17
Immunovia invitation to a teleconference on 24 August 2016

Immunovia invites you to a teleconference in connection with the publishing of the first half-year report for 2016. The conference call will take place at 10 a.m. on 24 August and the results will be published at around 8.30 a.m. the same day
Press release PDF

2016-08-16
Immunovia announces intention to apply for listing on Nasdaq Stockholm's Main Market

The Board of Immunovia AB (publ) ("Immunovia" or the "Company") today announces its intention to apply during the first half of 2017 for a listing of its shares on Nasdaq Stockholm's Main Market. Immunovia’s shares are currently admitted for trading on the Nasdaq First North under the IMMNOV ticker.
Press release PDF

2016-07-15
Prof. Diane Simeone from University of Michigan Medical Center becomes latest appointment to Immunovia Scientific Advisory Board

Extensive expertise in clinical tumor management and tumor biomarkers, will help accelerate pancreatic cancer diagnostic program
Press release PDF

2016-07-05
World leading cancer diagnostics expert, Professor Aldo Scarpa appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Aldo Scarpa has been appointed to the company’s Scientific Advisory Board. Professor Scarpa is the Director of the ARC-Net Research Centre for Applied Research on Cancer and Chair of the Department of Pathology and Diagnostics at the University and Hospital Trust of Verona in Italy.
Press release PDF

2016-06-23
Leading US gastrointestinal cancer expert, Professor Margaret Tempero appointed to Immunovia’s Scientific Advisory Board

LUND, Sweden ― As Immunovia maintains progress towards delivering the first validated test for early diagnosis of pancreatic cancer, the company announced today that Professor Margaret Tempero has been appointed to the company’s Scientific Advisory Board. Currently, Professor Tempero is Director of the UCSF Pancreas Center and leader of the Pancreas Cancer Program at the UCSF.
Press release PDF

2016-05-31
Stämmokommuniké

Årsstämma i Immunovia AB (publ), 556730-4299 har hållits lokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund den 30 maj 2016. Nedan följer en sammanfattning av de beslut som fattades.
Press release PDF

2016-05-30
Double pancreatic cancer survival by 2020

World Pancreatic Cancer Coalition (WPCC) and American Association for Cancer Research (AACR) Pancreatic Cancer Special Conference brought together patient advocacy groups and outstanding professionals 10-15 May, 2016 in Orlando, Florida to discuss pancreatic cancer, a disease with the lowest survival rates of any major cancer Prof Borrebaeck presented in his AACR talk how serum biomarker signatures can detect early stages of pancreatic cancer
Press release PDF

2016-05-30
96 % of early stage pancreatic cancer patients detected in a clinical validation study with a North American sample cohort

Second study validates Immunovia´s IMMray™ PanCan-d test for early detection of pancreatic cancer  
Press release PDF

2016-05-18
Inbjudan till Immunovia Informationsmöte i Stockholm den 1 juni kl 17.30 med VD MatsGrahn och Styrelseordförande Carl Borrebaeck

Aktieägare som inte har möjlighet att deltaga på Immunovias bolagsstämma den 30 maj i Lund samt övriga intresserade hälsas välkomna till ett informationsmöte där VD Mats Grahn och Styrelseordförande Carl Borrebaeck informerar om bolagets utveckling under 2015 och därefter.

2016-05-09
IMMUNOVIA JOINS MORE THAN 40 GLOBAL PANCREATIC CANCER ORGANIZATIONS AT INAGURAL MEETING

World Pancreatic Cancer Coalition Aims to Raise Unprecedented Awareness for a Disease with the Lowest Survival Rate of Any Major Cancer.  
PR Immunovia World Pancreatic Cancer Coalition

2016-04-26
Immunovia kallar till årsstämma 2016

Styrelsen i Immunovia AB (publ) har kallat  till årsstämma den 30 maj 2016. Stämman kommer att hållas kl 16.00 i samlingslokalen BioForum, hus 406, Medicon Village, Scheelevägen 2, 223 63 Lund.
PDF Press release

2016-04-08
Immunovia appoints Dr. Marco Del Chiaro from Karolinska Institute to Scientific Advisory Board

Dr. Del Chiaro brings deep experience in surgery of pancreatic diseases and identification of high risk individuals for pancreatic cancer.
Press release PDF

2016-04-01
NOTE about Immunovia and IMMray™ technology information on newswires and social media



2016-03-09
Immunovia partners with leading healthcare consultingservices firm

Immunovia partners with leading healthcare consulting services firm to support market access of pancreatic cancer test in Germany * Immunovia announces agreement with Ehlers, Ehlers and Partner to develop and drive market access strategy of IMMray™ PanCan-d in Germany
PDF Press release

2016-03-08
Immunovia launches Swedish website



2016-02-29
Immunovia starts collaboration with multinational life science company on new systemic lupus erythematosus (SLE) diagnostics test

Immunovia and a large multinational life science company have agreed to run two studies aimed at evaluating Immunovia’s IMMray™ SLE-d for diagnosis of SLE
Press release PDF

2016-02-24
Immunovia Year-end report 2015


Year-end report 2015

2016-02-10
Immunovia and Lund University start clinical validation studies of Systemic Lupus Erythematosus (SLE) biomarker signatures

Immunovia initiates a new program to focus on the development, validation and commercialization of antibody array based tests for differential diagnostics and for prediction/monitoring of flares for SLE also known as “lupus”. 
Release

2016-02-09
Immunovia announces collaboration with Mount Sinai Health System to validate early detection blood test for pancreatic cancer

LUND, Sweden, and NEW YORK, USA ― Immunovia AB is pleased to announce that Mount Sinai Health System will be one of the first sites participating in a prospective clinical study for the early diagnosis of pancreatic cancer. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting second half of 2016.
Release

2016-01-19
Immunovia and the University of Liverpool enter into a collaboration in a prospective clinical study

LUND, Sweden, and Liverpool, UK ― Immunovia and the University of Liverpool enter into collaboration to validate early detection blood test for pancreatic cancer in a prospective clinical study. In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced today that the first European site participating in its prospective clinical study for the early diagnosis of pancreatic cancer will be the National Institute for Health Research (NIHR) Pancreatic Biomedical Research Unit, based at the Royal Liverpool University Hospital. Designed to validate Immunovia´s blood test, IMMray™ PanCan-d, the study will run for three years across sites in both the US and Europe, starting in the second half of 2016.
Release

2015-12-18
White Paper outlines predicted impact of new biomarker diagnostic technology on pancreatic cancer survival rates

LUND, Sweden ― In this White Paper, Immunovia summarizes the clinical evidence retrospective studies performed so far on pancreatic cancer with IMMray™ PanCan-d. The blood based biomarker signature is able to detect pancreatic cancer in all stages, especially in resectable stage I and II, and thus has the potential to improve 5-year patient survival rates from 4-6% to 50-60%.
Release

2015-12-03
IMMray™ PanCan-d detects 98% of pancreatic cancers in retrospective study with 1400 blood samples

Largest ever study for diagnosing pancreatic cancer paves way for early intervention to significantly improve survival rates.
Release

2015-12-02
Immunovia’s stock increased 60 percent on first day of trading on Nasdaq First North with a turnover of SEK 28.5 million

Trading in Immunovia AB’s shares (IMMNOV) commenced yesterday on Nasdaq First North in Stockholm. At closing the share price had surged 60 percent compared to the introduction price. The interest among investors was high. The trading turnover was SEK 28.5 million during the day, thus setting a new record among comparable First North listings during 2015.

2015-11-26
Immunovia approved for trading on Nasdaq First North as of December 1st, 2015

Immunovia AB (publ) has been approved for trading of its shares on Nasdaq First North in Stockholm. The first trading day is December 1st, 2015. Immunovia is a Swedish research company that has developed a new method for using a blood test to diagnose pancreatic cancer. With Immunovia’s test, diagnosis can be made earlier which substantially enhances the possibilities to treat the cancer. A new share issue of SEK 60 million before issue costs have been carried out before introduction on First North.
Release

2015-10-05
Immunovia, OHSU collaborating on early detection test for pancreatic cancer

LUND, Sweden, and PORTLAND, Oregon ― Immunovia AB and the Knight Cancer Institute at Oregon Health & Science University (OHSU) formed a collaboration to confirm, validate and commercialize a blood test for the early diagnosis of pancreatic cancer. The test called IMMray™ PanCan-d analyses a patient’s immune system for early signs of disease. The collaboration will also enable researchers to explore biomarkers for a number of other cancer types.
Press release: Immunovia, OHSU collaborating on early detection test for pancreatic cancer